Safety of the first dose of fingolimod for multiple sclerosis: Results of an open-label clinical trial

BMC Neurology

Volumn 14, Issue 1, 2014, Pages

  Laroni, Alice ^a   Brogi, Davide ^a   Morra, Vincenzo B ^b   Guidi, Leonello ^c   Pozzilli, Carlo ^d   Comi, Giancarlo ^e   Lugaresi, Alessandra ^f   Turrini, Renato ^g   Raimondi, Debora ^g   Uccelli, Antonio ^a   Mancardi, Giovanni L ^a   Amato, M P ^h   Appendino, L ^h   Ardito, B ⁱ   Avolio, C ^h   Bandini, F ^h   Batocchi, A P ^h   Bellantonio, P ^h   Benedetti, M D ^h   Bergamaschi, R ^h   Bortolon, F ^h   Bosco, A ^h   Buccafusca, M ^h   Cargnelutti, D ^h   Cavalla, P ^h   Cavallo, R ^h   Centonze, D ^h   Coniglio, M G ^h   Costantino, G ^h   Cottone, S ^h   Danni, M C ^h   De Robertis, F ^h   Deotto, L ^h   Dotta, M ^h   Di Battista, G ^h   Filippi, M M ^h   Florio, C ^h   Francia, A ^h   Galgani, S ^h   Gallo, P ^h   Ghezzi, A ^h   Giometto, B ^h   Giuliani, G ^h   Grimaldi, L M E ^h   Guidotti, M ^h   Iudice, A ^h   Lenzi, G L ^h   Lorusso, L ^h   Lus, G ^h   Maimone, D ^h   Malentacchi, G M ^h   Mantegazza, R E ^h   Massacesi, L ^h   Melato, M ^h   Millefiorini, E ^h   Montanari, E ^h   Patti, F ^h   Perrone, P S M ^h   Protti, A ^h   Provera, P ^h   Quattrone, A ^h   Rasi, F ^h   Rosati, G ^h   Rovaris, M ^h   Sacca F ^h   Salemi, G ^h   Sarchielli, P ^h   Scarpini, E A ^h   Schoenhuber, R ^h   Serrati, C ^h   Sinisi, L ^h   Sola, P ^h   Spitaleri, D L A ^h   Tedeschi, G ^h   Tezzon, F ^h   Tinebra Asti, M C ^h   Tola, M R ^h   Totaro, R ^h   Trojano, M ^h   Ulivelli, M ^h   Vecchio, M M ^h   Zimatore, G B ^h   more..

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c SAN GIUSEPPE HOSPITAL   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^f UNIVERSITY OF CHIETI   (Italy)

^g Italy   (Italy)

^h Acquaviva delle Fonti ^*

ⁱ Centro di Salute Mentale Acquaviva delle Fonti   (Italy)

Author keywords

Atrioventricular block; Bradycardia; Fingolimod; Multiple sclerosis; Safety; Tolerability

Indexed keywords

4 AMINOPYRIDINE; AMANTADINE; AMFEBUTAMONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DULOXETINE; ESCITALOPRAM; FINGOLIMOD; MACROLIDE; MIRTAZAPINE; MODAFINIL; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SOLIFENACIN; TIZANIDINE; TOLTERODINE; TOPIRAMATE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; IMMUNOSUPPRESSIVE AGENT; PROPANEDIOL DERIVATIVE; SPHINGOSINE;

ADULT; ARTICLE; ASTHENIA; BLURRED VISION; BRADYCARDIA; CARDIOVASCULAR DISEASE; CHILL; COHORT ANALYSIS; CONNECTIVE TISSUE DISEASE; DIARRHEA; DIZZINESS; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; FEMALE; FIRST DEGREE ATRIOVENTRICULAR BLOCK; HEADACHE; HEART PALPITATION; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HYPERPYREXIA; INFECTION; ITALY; LIMB PAIN; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; MUSCULOSKELETAL DISEASE; NAUSEA; NEURALGIA; OPEN STUDY; OUTCOME ASSESSMENT; PARESTHESIA; RHINOPHARYNGITIS; SECOND DEGREE ATRIOVENTRICULAR BLOCK; SINUS ARRHYTHMIA; SOMNOLENCE; THORAX PAIN; URINARY TRACT INFECTION; VERTIGO; VITAL SIGN; VOMITING; ADOLESCENT; ANALOGS AND DERIVATIVES; ATRIOVENTRICULAR BLOCK; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG COMBINATION; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; ATRIOVENTRICULAR BLOCK; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PROPYLENE GLYCOLS; SPHINGOSINE; YOUNG ADULT;

EID: 84899660109     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-14-65     Document Type: Article

References (14)

1. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L, TRANSFORMS Study Group Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010, 362:402-415. 10.1056/NEJMoa0907839, 20089954, TRANSFORMS Study Group.
2. Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006, 355:1124-1140. 10.1056/NEJMoa052643, 16971719.
3. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010, 362:387-401. 10.1056/NEJMoa0909494, 20089952.
4. Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther 2007, 115:84-105. 10.1016/j.pharmthera.2007.04.006, 17561264.
5. Budde K, Schmouder RL, Brunkhorst R, Nashan B, Lücker PW, Mayer T, Choudhury S, Skerjanec A, Kraus G, Neumayer HH. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol 2002, 13:1073-1083.
6. DiMarco JP, O'Connor P, Cohen JA, Reder AT, Zhang-Auberson L, Tang D, Collins W, Kappos L. Fingolimod treatment initiation experience: cardiac and Holter electrocardiogram findings from three phase 3 studies. Multiple Sclerosis Journal 2012, 18:117. P530.
7. Espinosa PS, Berger JR. Delayed fingolimod-associated asystole. Multiple Sclerosis Journal 2011, 17:1387-1389. 10.1177/1352458511410344, 21652609.
8. Cocco G. A patient with Leiden V mutation, multiple sclerosis, psoriasis, and sicca syndrome: could celecoxib and fingolimod adversely affect the heart?. Cardiovasc Toxicol 2012, 12:266-272. 10.1007/s12012-012-9166-y, 22528818.
9. Questions and answers on the review of Gilenya [http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2012/04/WC500125689.pdf (accessed 12 April 2013)].
10. FDA Drug Safety Communication: Revised recommendations for cardiovascular monitoring and use of multiple sclerosis drug Gilenya (fingolimod) [http://www.fda.gov/Drugs/DrugSafety/ucm303192.htm#data].
11. Giovannoni G, Southam E, Waubant E. Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence. Multiple Sclerosis Journal 2012, 18:932-946. 10.1177/1352458511433302, 22249762.
12. Hohlfeld R, Barkhof F, Polman C. Future clinical challenges in multiple sclerosis: Relevance to sphingosine 1-phosphate receptor modulator therapy. Neurology 2011, 76:S28-S37. 10.1212/WNL.0b013e31820db40f, 21339488.
13. Uitdehaag BMJ, Barkhof F, Coyle PK, Gardner JD, Jeffery DR, Mikol DD. The changing face of multiple sclerosis clinical trial populations. Curr Med Res Opin 2011, 27:1529-1537. 10.1185/03007995.2011.591370, 21671851.
14. Hughes B, Cascione M, McCague K, Pestreich L, Schofield L, Kim E, Barbato L. Cardiac effects of fingolimod after first dose administration and therapy change in patients with multiple sclerosis. Neurology 2013, 80(Meeting Abstracts 1):P01.170.